United States Biotechnology & Medical Research

Cullinan Therapeutics Inc (CGEM)

Track

Over the last 90 days, Cullinan Therapeutics Inc. has seen significant insider selling, with a net value of -$818,873.43. Executives were responsible for all of this net selling. Notably, Jennifer Michaelson, Chief Scientific Officer, and other executives engaged in multiple planned and proposed sales totaling over $1.2 million. The stock has experienced a modest 2.1% price increase over the same period.
Stock chart
Ticker: CGEM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Michaelson Jennifer
Chief Scientific Officer
2 sales — total 116,996 USD
Planned sale 5 May 2026
Value US$195,221.43 | Price 20.78 | Shares 30,861
Planned sale 5 May 2026
Value US$3,299,200.75 | Price 143.14 | Shares 47,820
Proposed sale 5 May 2026
Value US$4,730,642.79 | Price 46.31 | Shares 26,516
Planned sale 5 Mar 2026
Value US$125,440.00 | Price 15.68 | Shares 8,000
Proposed sale 5 Mar 2026
Value US$130,400.00 | Price 16.30 | Shares 8,000
Planned sale 25 Feb 2026
Value US$25,169.20 | Price 14.14 | Shares 1,780
Proposed sale 25 Feb 2026
Value US$25,400.60 | Price 14.27 | Shares 1,780
Sale 24 Feb 2026
Value US$66,301.54 | Price 14.47 | Shares 4,582
Sale 24 Feb 2026
Value US$52,106.47 | Price 14.47 | Shares 3,601
Sale 24 Feb 2026
Value US$195,562.05 | Price 14.47 | Shares 13,515
Sale 24 Feb 2026
Value US$52,106.47 | Price 14.47 | Shares 3,601
Planned sale 23 Feb 2026
Value US$24,510.48 | Price 13.99 | Shares 1,752
Proposed sale 23 Feb 2026
Value US$23,914.80 | Price 13.65 | Shares 1,752
Sale 20 Feb 2026
Value US$59,900.76 | Price 13.62 | Shares 4,398
Sale 20 Feb 2026
Value US$223,109.22 | Price 13.62 | Shares 16,381
Planned sale 20 Feb 2026
Value US$114,400.00 | Price 14.30 | Shares 8,000
Sale 20 Feb 2026
Value US$50,966.04 | Price 13.62 | Shares 3,742
Sale 20 Feb 2026
Value US$50,966.04 | Price 13.62 | Shares 3,742
Sale 20 Feb 2026
Value US$67,854.84 | Price 13.62 | Shares 4,982
Proposed sale 20 Feb 2026
Value US$111,040.00 | Price 13.88 | Shares 8,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-06 2026-05-05 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
30,861 -12.2%
20.78
US$195,221 		30,861 -12.2% 20.78 US$195,221
2026-05-06 2026-05-05 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
47,820 +41.2%
143.14
US$3,299,201 		47,820 +41.2% 143.14 US$3,299,201
2026-05-05 2026-05-05 PrS Proposed sale
3.3
JENNIFER MICHAELSON

Officer

Officer
26,516
46.31
US$4,730,643 		26,516 46.31 US$4,730,643
2026-03-09 2026-03-05 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -4.5%
15.68
US$125,440 		8,000 -4.5% 15.68 US$125,440
2026-03-05 2026-03-05 PrS Proposed sale
3.3
JENNIFER MICHAELSON

Officer

Officer
8,000
16.30
US$130,400 		8,000 16.30 US$130,400
2026-02-26 2026-02-25 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
1,780 -1.0%
14.14
US$25,169 		1,780 -1.0% 14.14 US$25,169
2026-02-25 2026-02-25 PrS Proposed sale
3.3
JENNIFER MICHAELSON

Officer

Officer
1,780
14.27
US$25,401 		1,780 14.27 US$25,401
2026-02-25 2026-02-24 S Sale
2.9
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,582 -2.8%
14.47
US$66,302 		4,582 -2.8% 14.47 US$66,302
2026-02-25 2026-02-24 S Sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
3,601 -2.0%
14.47
US$52,106 		3,601 -2.0% 14.47 US$52,106
2026-02-25 2026-02-24 S Sale
2.5
AHMED NADIM

President and CEO

Executive Director
13,515 -3.3%
14.47
US$195,562 		13,515 -3.3% 14.47 US$195,562
2026-02-25 2026-02-24 S Sale
3.3
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,601 -2.7%
14.47
US$52,106 		3,601 -2.7% 14.47 US$52,106
2026-02-25 2026-02-23 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
1,752 -1.0%
13.99
US$24,510 		1,752 -1.0% 13.99 US$24,510
2026-02-23 2026-02-23 PrS Proposed sale
3.3
JENNIFER MICHAELSON

Officer

Officer
1,752
13.65
US$23,915 		1,752 13.65 US$23,915
2026-02-23 2026-02-20 S Sale
Fenton Mary Kay

Chief Financial Officer

Officer
4,398 -3.4%
13.62
US$59,901 		4,398 -3.4% 13.62 US$59,901
2026-02-23 2026-02-20 S Sale
2.5
AHMED NADIM

President and CEO

Executive Director
16,381 -3.9%
13.62
US$223,109 		16,381 -3.9% 13.62 US$223,109
2026-02-23 2026-02-20 PlS Planned sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -4.2%
14.30
US$114,400 		8,000 -4.2% 14.30 US$114,400
2026-02-23 2026-02-20 S Sale
3.3
Michaelson Jennifer

Chief Scientific Officer

Officer
3,742 -2.0%
13.62
US$50,966 		3,742 -2.0% 13.62 US$50,966
2026-02-23 2026-02-20 S Sale
3.3
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,742 -2.8%
13.62
US$50,966 		3,742 -2.8% 13.62 US$50,966
2026-02-23 2026-02-20 S Sale
2.9
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,982 -2.9%
13.62
US$67,855 		4,982 -2.9% 13.62 US$67,855
2026-02-20 2026-02-20 PrS Proposed sale
3.3
JENNIFER MICHAELSON

Officer

Officer
8,000
13.88
US$111,040 		8,000 13.88 US$111,040
Explore more

More insider trading research around Cullinan Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America